vs

Side-by-side financial comparison of Consolidated Water Co. Ltd. (CWCO) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Consolidated Water Co. Ltd. is the larger business by last-quarter revenue ($29.6M vs $19.6M, roughly 1.5× STANDARD BIOTOOLS INC.). Consolidated Water Co. Ltd. runs the higher net margin — 10.3% vs -177.4%, a 187.7% gap on every dollar of revenue. On growth, Consolidated Water Co. Ltd. posted the faster year-over-year revenue change (4.4% vs -11.5%). Consolidated Water Co. Ltd. produced more free cash flow last quarter ($3.4M vs $-23.1M). Over the past eight quarters, STANDARD BIOTOOLS INC.'s revenue compounded faster (-12.2% CAGR vs -13.6%).

Coca-Cola Consolidated, Inc., headquartered in Charlotte, North Carolina, is the largest independent Coca-Cola bottler in the United States.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CWCO vs LAB — Head-to-Head

Bigger by revenue
CWCO
CWCO
1.5× larger
CWCO
$29.6M
$19.6M
LAB
Growing faster (revenue YoY)
CWCO
CWCO
+15.8% gap
CWCO
4.4%
-11.5%
LAB
Higher net margin
CWCO
CWCO
187.7% more per $
CWCO
10.3%
-177.4%
LAB
More free cash flow
CWCO
CWCO
$26.5M more FCF
CWCO
$3.4M
$-23.1M
LAB
Faster 2-yr revenue CAGR
LAB
LAB
Annualised
LAB
-12.2%
-13.6%
CWCO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CWCO
CWCO
LAB
LAB
Revenue
$29.6M
$19.6M
Net Profit
$3.0M
$-34.7M
Gross Margin
34.7%
48.5%
Operating Margin
9.1%
-168.5%
Net Margin
10.3%
-177.4%
Revenue YoY
4.4%
-11.5%
Net Profit YoY
91.5%
-28.8%
EPS (diluted)
$0.18
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWCO
CWCO
LAB
LAB
Q4 25
$29.6M
Q3 25
$35.1M
$19.6M
Q2 25
$33.6M
$21.8M
Q1 25
$33.7M
$40.8M
Q4 24
$28.4M
Q3 24
$33.4M
$22.1M
Q2 24
$32.5M
$22.5M
Q1 24
$39.7M
$45.5M
Net Profit
CWCO
CWCO
LAB
LAB
Q4 25
$3.0M
Q3 25
$5.5M
$-34.7M
Q2 25
$5.1M
$-33.5M
Q1 25
$4.8M
$-26.0M
Q4 24
$1.6M
Q3 24
$4.5M
$-26.9M
Q2 24
$15.9M
$-45.7M
Q1 24
$6.5M
$-32.2M
Gross Margin
CWCO
CWCO
LAB
LAB
Q4 25
34.7%
Q3 25
36.9%
48.5%
Q2 25
38.2%
48.8%
Q1 25
36.5%
48.4%
Q4 24
29.9%
Q3 24
34.8%
54.9%
Q2 24
35.8%
46.1%
Q1 24
35.0%
53.1%
Operating Margin
CWCO
CWCO
LAB
LAB
Q4 25
9.1%
Q3 25
16.4%
-168.5%
Q2 25
15.7%
-118.1%
Q1 25
13.7%
-80.8%
Q4 24
3.8%
Q3 24
14.6%
-120.9%
Q2 24
15.4%
-134.5%
Q1 24
18.4%
-132.2%
Net Margin
CWCO
CWCO
LAB
LAB
Q4 25
10.3%
Q3 25
15.8%
-177.4%
Q2 25
15.2%
-153.7%
Q1 25
14.2%
-63.8%
Q4 24
5.6%
Q3 24
13.3%
-122.0%
Q2 24
48.8%
-203.3%
Q1 24
16.3%
-70.6%
EPS (diluted)
CWCO
CWCO
LAB
LAB
Q4 25
$0.18
Q3 25
$0.34
$-0.09
Q2 25
$0.32
$-0.09
Q1 25
$0.30
$-0.07
Q4 24
$0.10
Q3 24
$0.28
$-0.07
Q2 24
$0.99
$-0.12
Q1 24
$0.40
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWCO
CWCO
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$123.8M
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$221.7M
$399.7M
Total Assets
$257.6M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWCO
CWCO
LAB
LAB
Q4 25
$123.8M
Q3 25
$123.6M
$129.4M
Q2 25
$112.2M
$158.6M
Q1 25
$107.9M
$150.9M
Q4 24
$99.4M
Q3 24
$104.9M
$210.6M
Q2 24
$96.7M
$269.8M
Q1 24
$46.2M
$287.1M
Total Debt
CWCO
CWCO
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CWCO
CWCO
LAB
LAB
Q4 25
$221.7M
Q3 25
$220.4M
$399.7M
Q2 25
$216.6M
$424.5M
Q1 25
$213.3M
$454.6M
Q4 24
$210.0M
Q3 24
$209.8M
$489.3M
Q2 24
$206.7M
$510.3M
Q1 24
$192.1M
$577.3M
Total Assets
CWCO
CWCO
LAB
LAB
Q4 25
$257.6M
Q3 25
$257.2M
$539.6M
Q2 25
$257.5M
$557.0M
Q1 25
$250.4M
$579.6M
Q4 24
$243.3M
Q3 24
$238.4M
$681.5M
Q2 24
$235.2M
$708.7M
Q1 24
$223.2M
$777.7M
Debt / Equity
CWCO
CWCO
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWCO
CWCO
LAB
LAB
Operating Cash FlowLast quarter
$5.8M
$-22.2M
Free Cash FlowOCF − Capex
$3.4M
$-23.1M
FCF MarginFCF / Revenue
11.4%
-118.1%
Capex IntensityCapex / Revenue
8.1%
4.5%
Cash ConversionOCF / Net Profit
1.90×
TTM Free Cash FlowTrailing 4 quarters
$33.2M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWCO
CWCO
LAB
LAB
Q4 25
$5.8M
Q3 25
$15.4M
$-22.2M
Q2 25
$8.8M
$-20.7M
Q1 25
$11.8M
$-30.3M
Q4 24
$-742.0K
Q3 24
$10.4M
$-27.9M
Q2 24
$21.0M
$-39.0M
Q1 24
$6.0M
$-62.5M
Free Cash Flow
CWCO
CWCO
LAB
LAB
Q4 25
$3.4M
Q3 25
$13.5M
$-23.1M
Q2 25
$6.1M
$-22.6M
Q1 25
$10.2M
$-35.3M
Q4 24
$-3.7M
Q3 24
$8.3M
$-30.1M
Q2 24
$19.8M
$-41.0M
Q1 24
$5.4M
$-63.3M
FCF Margin
CWCO
CWCO
LAB
LAB
Q4 25
11.4%
Q3 25
38.4%
-118.1%
Q2 25
18.3%
-103.6%
Q1 25
30.1%
-86.6%
Q4 24
-13.0%
Q3 24
24.9%
-136.4%
Q2 24
60.8%
-182.2%
Q1 24
13.7%
-138.9%
Capex Intensity
CWCO
CWCO
LAB
LAB
Q4 25
8.1%
Q3 25
5.5%
4.5%
Q2 25
7.8%
8.7%
Q1 25
4.7%
12.4%
Q4 24
10.4%
Q3 24
6.1%
10.2%
Q2 24
3.7%
8.6%
Q1 24
1.3%
1.7%
Cash Conversion
CWCO
CWCO
LAB
LAB
Q4 25
1.90×
Q3 25
2.79×
Q2 25
1.72×
Q1 25
2.45×
Q4 24
-0.47×
Q3 24
2.32×
Q2 24
1.32×
Q1 24
0.92×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CWCO
CWCO

Services Revenues$10.5M35%
Transferred At Point In Time$8.5M29%
Operations And Maintenance$8.4M28%
Transferred Over Time$1.9M7%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons